Enhanced platelet aggregation as a risk factor for vascular disease and its thromboembolic complications

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.

Diabetes, obesity & metabolism·2015

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.

Diabetes, obesity & metabolism·2015

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Diabetes, obesity & metabolism·2015

A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2003

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Diabetes care·2000

Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.

Circulation·1999

Paliperidone-induced diabetes mellitus presenting with hyperosmolar hyperglycemic state: a case report.

Acta clinica Belgica·2026

Early-onset respiratory adverse event patterns of omalizumab in pediatric patients: an age-stratified FAERS pharmacovigilance study.

Acta clinica Belgica·2026

Mpox vaccination in Belgium: clinical guidance for implementation readiness.

Acta clinica Belgica·2026

Left atrial volume index in patients with Rosacea: a retrospective case-control study.

Acta clinica Belgica·2026

Atherogenic and inflammatory biomarkers in NSTEMI: a comparative analysis of predictive value for obstructive coronary disease.

Acta clinica Belgica·2026

Discordance between symptomatic, echocardiographic and renal trajectories after SGLT2 inhibitor initiation in heart failure: a landmark analysis of the prospective CaRD registry.

Acta clinica Belgica·2026

Long-term outcome of pediatric anti-complement factor H antibody-associated atypical hemolytic uremic syndrome receiving abbreviated plasma exchange: a retrospective study from a single center.

Journal of nephrology·2026

[Therapeutic apheresis in first-line treatment of hematological disorders - an evidence-based review].

Therapeutische Umschau. Revue therapeutique·2026

Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization.

Transfusion·2026

Platelet-erythrocyte complex production is exacerbated by histones and protected by small polyanion histone neutralizing compounds.

Platelets·2026

Changing the treatment paradigm in beta thalassemia.

Folia medica·2026

Noninvasive Thrombus Imaging in Patients With Ischemic Stroke.

Circulation·2026

Related Experiment Videos

Enhanced platelet aggregation as a risk factor for vascular disease and its thromboembolic complications

Related Concept Videos

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.

Paliperidone-induced diabetes mellitus presenting with hyperosmolar hyperglycemic state: a case report.

Early-onset respiratory adverse event patterns of omalizumab in pediatric patients: an age-stratified FAERS pharmacovigilance study.

Mpox vaccination in Belgium: clinical guidance for implementation readiness.

Left atrial volume index in patients with Rosacea: a retrospective case-control study.

Atherogenic and inflammatory biomarkers in NSTEMI: a comparative analysis of predictive value for obstructive coronary disease.

Discordance between symptomatic, echocardiographic and renal trajectories after SGLT2 inhibitor initiation in heart failure: a landmark analysis of the prospective CaRD registry.

Long-term outcome of pediatric anti-complement factor H antibody-associated atypical hemolytic uremic syndrome receiving abbreviated plasma exchange: a retrospective study from a single center.

[Therapeutic apheresis in first-line treatment of hematological disorders - an evidence-based review].

Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization.

Platelet-erythrocyte complex production is exacerbated by histones and protected by small polyanion histone neutralizing compounds.

Changing the treatment paradigm in beta thalassemia.

Noninvasive Thrombus Imaging in Patients With Ischemic Stroke.

Related Experiment Videos

Enhanced platelet aggregation as a risk factor for vascular disease and its thromboembolic complications

Related Concept Videos

Related Articles